NCT03600701 2025-10-07Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting51 enrolled
NCT03202940 2025-09-25A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCMassachusetts General HospitalPhase 1/2 Active not recruiting16 enrolled